Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Virol ; 77(13): 7486-91, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12805448

ABSTRACT

Guinea pigs immunized intranasally with a keyhole limpet hemocyanin-linked peptide, corresponding to the prominent G-H loop of the VP1 protein of foot-and-mouth disease virus, raised substantial levels of antipeptide and virus-neutralizing antibodies in sera and of peptide-specific secretory immunoglobulin A in nasal secretions. In groups of animals immunized intranasally without adjuvant, 86 percent were fully protected upon challenge with homotypic virus. Surprisingly, animals given the peptide conjugates plus the mucosal adjuvant cholera toxin were afforded only partial protection in that primary lesions were observed in most animals, although spread to other feet was prevented. These results indicate that intranasal inoculation with the peptide offers a potential route of vaccination against foot-and-mouth disease and may be useful for eliciting protection in the upper respiratory tracts of susceptible animals.


Subject(s)
Antibodies, Viral/biosynthesis , Foot-and-Mouth Disease Virus/immunology , Immunity, Mucosal , Immunodominant Epitopes/immunology , Viral Vaccines/immunology , Administration, Intranasal , Amino Acid Sequence , Animals , Female , Foot-and-Mouth Disease Virus/chemistry , Guinea Pigs , Molecular Sequence Data , Neutralization Tests , Viral Vaccines/administration & dosage
2.
Am J Health Syst Pharm ; 58(7): 607-14, 2001 Apr 01.
Article in English | MEDLINE | ID: mdl-11296612

ABSTRACT

The treatment of hyperlipidemia in patients infected with HIV is discussed. Hyperlipidemia is common in HIV-infected patients receiving antiretroviral therapy, especially protease inhibitors and stavudine. The recommendations of the National Cholesterol Education Program (NCEP) may not entirely apply to HIV-infected patients. The pathogenesis of hyperlipidemia in these patients may make them refractory to traditional pharmacotherapy, and NCEP's emphasis on diet and exercise may be unrealistic. Other factors that may complicate treatment of hyperlipidemia include metabolism of many antiretroviral drugs by the cytochrome P-450 isoenzyme system, polypharmacy, and drug-food interactions. A patient's cardiac risk should first be assessed. Nonpharmacologic measures, such as a low-fat diet, weight reduction, and exercise, should be considered. Drug therapy is indicated for patients with familial combined hyperlipidemia that is associated with atherogenesis and for patients with triglyceride concentrations exceeding 1000 mg/dL. Drug therapy for hyperlipidemia involves niacin and statins, in addition to fibric acid derivatives and probucol. Switching among antiretroviral agents when one is found to cause hyperlipidemia should be done cautiously because of the risk for viral rebound and disease progression. NCEP guidelines recommend monitoring low-density-lipoprotein cholesterol levels four to six weeks after the start of lipid-lowering therapy and then at three months; more frequent monitoring may be necessary in HIV-infected patients. The treatment of hyperlipidemia in HIV-infected patients is complicated by their need for antiretroviral drugs, which can themselves contribute to lipid disorders.


Subject(s)
HIV Infections/complications , Hyperlipidemias/drug therapy , Hyperlipidemias/etiology , Hypolipidemic Agents/therapeutic use , Anti-HIV Agents/adverse effects , Humans , Hyperlipidemias/therapy
3.
Med Health R I ; 84(2): 55-8, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11272661

ABSTRACT

Mortality outcomes in clinical trials have become the foundation for the evidence-based management of patients with systolic heart failure. This review was intended to give the clinician a better understanding of newer pharmacological strategies in this patient population.


Subject(s)
Heart Failure/drug therapy , Heart Failure/mortality , Adrenergic beta-Antagonists/therapeutic use , Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Digoxin/therapeutic use , Humans , Mineralocorticoid Receptor Antagonists/adverse effects , Mineralocorticoid Receptor Antagonists/therapeutic use , Spironolactone/adverse effects , Spironolactone/therapeutic use , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...